Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | JNJ-86974680 |
| Trade Name | |
| Synonyms | JNJ 86974680|JNJ86974680 |
| Drug Descriptions |
JNJ-86974680 is an antagonist of the adenosine receptor A2AR (ADORA2A) expressed on T-lymphocytes, which may relieve adenosine-mediated immune suppression and enhance antitumor activity (Cancer Res (2025) 85 (8_Supplement_2): CT137; NCI Drug Dictionary). |
| DrugClasses | Adenosine Targeting 24 |
| CAS Registry Number | NA |
| NCIT ID | C202467 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cetrelimab + JNJ-86974680 | Cetrelimab JNJ-86974680 | 0 | 1 |
| JNJ-86974680 | JNJ-86974680 | 0 | 0 |